Video

CHICAGO – Adding the recently approved stomach cancer drug, ramucirumab (Cyramza) to docetaxel reduced the risk of death in second-line, non–small cell lung cancer by 14% in the phase III REVEL study.

This is the first therapy in roughly a decade to improve the outcome of lung cancer patients in the second-line setting, according to study author Dr. Maurice Perol, head of thoracic oncology at Cancer Research Center of Lyon, France.

In addition, the recombinant human monoclonal antibody showed benefits in nonsquamous carcinoma as well as the squamous subtype, where treatments are limited.

Still, the median survival gain of just 1.4 months did not impress all at the annual meeting of the American Society of Clinical Oncology, where the study was highlighted in a press briefing before its formal presentation.

To hear Dr. Perol wade through the data and controversy, listen to our interview online.

The study was supported by ImClone, a subsidiary of Eli Lilly, which markets ramucirumab. Dr. Perol reported serving as a consultant or adviser with Lilly, Pfizer, Roche, Boehringer Ingelheim, and Genentech.

CHICAGO – Adding the recently approved stomach cancer drug, ramucirumab (Cyramza) to docetaxel reduced the risk of death in second-line, non–small cell lung cancer by 14% in the phase III REVEL study.

This is the first therapy in roughly a decade to improve the outcome of lung cancer patients in the second-line setting, according to study author Dr. Maurice Perol, head of thoracic oncology at Cancer Research Center of Lyon, France.

In addition, the recombinant human monoclonal antibody showed benefits in nonsquamous carcinoma as well as the squamous subtype, where treatments are limited.

Still, the median survival gain of just 1.4 months did not impress all at the annual meeting of the American Society of Clinical Oncology, where the study was highlighted in a press briefing before its formal presentation.

To hear Dr. Perol wade through the data and controversy, listen to our interview online.

The study was supported by ImClone, a subsidiary of Eli Lilly, which markets ramucirumab. Dr. Perol reported serving as a consultant or adviser with Lilly, Pfizer, Roche, Boehringer Ingelheim, and Genentech.

CHICAGO – Adding the recently approved stomach cancer drug, ramucirumab (Cyramza) to docetaxel reduced the risk of death in second-line, non–small cell lung cancer by 14% in the phase III REVEL study.

This is the first therapy in roughly a decade to improve the outcome of lung cancer patients in the second-line setting, according to study author Dr. Maurice Perol, head of thoracic oncology at Cancer Research Center of Lyon, France.

In addition, the recombinant human monoclonal antibody showed benefits in nonsquamous carcinoma as well as the squamous subtype, where treatments are limited.

Still, the median survival gain of just 1.4 months did not impress all at the annual meeting of the American Society of Clinical Oncology, where the study was highlighted in a press briefing before its formal presentation.

To hear Dr. Perol wade through the data and controversy, listen to our interview online.

The study was supported by ImClone, a subsidiary of Eli Lilly, which markets ramucirumab. Dr. Perol reported serving as a consultant or adviser with Lilly, Pfizer, Roche, Boehringer Ingelheim, and Genentech.

PARIS – Newly discovered micro RNA molecules found in the blood of patients before they developed severe osteoarthritis may help predict the disease and potentially identify those who would most benefit from preventive interventions.

That finding emerged from a longitudinal study presented at the annual European Congress of Rheumatology.

By using a screening technique to search a broad array of micro RNAs (miRNAs), Dr. Christian Beyer of the University of Erlangen-Nuremberg (Germany) and his colleagues found several miRNAs that were differentially expressed in the blood of 67 people who developed severe osteoarthritis and underwent at least one total joint replacement and 749 who did not.

One miRNA molecule in particular, known as let-7e, appeared to be "very promising" in this regard, he said. Let-7e is inversely associated with the development of osteoarthritis, with levels correlating with the risk of developing OA, Dr. Beyer said in a video interview with Dr. Christopher Sparks of the University of Liverpool (England).

jevans@frontlinemedcom.com

PARIS – Newly discovered micro RNA molecules found in the blood of patients before they developed severe osteoarthritis may help predict the disease and potentially identify those who would most benefit from preventive interventions.

That finding emerged from a longitudinal study presented at the annual European Congress of Rheumatology.

By using a screening technique to search a broad array of micro RNAs (miRNAs), Dr. Christian Beyer of the University of Erlangen-Nuremberg (Germany) and his colleagues found several miRNAs that were differentially expressed in the blood of 67 people who developed severe osteoarthritis and underwent at least one total joint replacement and 749 who did not.

One miRNA molecule in particular, known as let-7e, appeared to be "very promising" in this regard, he said. Let-7e is inversely associated with the development of osteoarthritis, with levels correlating with the risk of developing OA, Dr. Beyer said in a video interview with Dr. Christopher Sparks of the University of Liverpool (England).

jevans@frontlinemedcom.com

PARIS – Newly discovered micro RNA molecules found in the blood of patients before they developed severe osteoarthritis may help predict the disease and potentially identify those who would most benefit from preventive interventions.

That finding emerged from a longitudinal study presented at the annual European Congress of Rheumatology.

By using a screening technique to search a broad array of micro RNAs (miRNAs), Dr. Christian Beyer of the University of Erlangen-Nuremberg (Germany) and his colleagues found several miRNAs that were differentially expressed in the blood of 67 people who developed severe osteoarthritis and underwent at least one total joint replacement and 749 who did not.

One miRNA molecule in particular, known as let-7e, appeared to be "very promising" in this regard, he said. Let-7e is inversely associated with the development of osteoarthritis, with levels correlating with the risk of developing OA, Dr. Beyer said in a video interview with Dr. Christopher Sparks of the University of Liverpool (England).

jevans@frontlinemedcom.com

PARIS – New guidelines aim to narrow the wide variation that has been observed across specialties and countries in the treatment of patients with polymyalgia rheumatica.

The guidelines, the first ever developed in a joint collaboration between the American College of Rheumatology and the European League Against Rheumatism, brought together "probably the biggest and most diverse guidelines panel" ever assembled for a rheumatologic condition – with 51 members, including patients, according to Dr. Bhaskar Dasgupta, primary author of the guidelines and leader of the guidelines study group.

Within the guidelines is a flowchart for the treatment of polymyalgia rheumatica that outlines overarching principles for care involving clinical, laboratory, and imaging assessments, as well as patient views, said Dr. Dasgupta, head of the department of rheumatology at Southend University Hospital, Essex, England.

jevans@frontlinemedcom.com

PARIS – New guidelines aim to narrow the wide variation that has been observed across specialties and countries in the treatment of patients with polymyalgia rheumatica.

The guidelines, the first ever developed in a joint collaboration between the American College of Rheumatology and the European League Against Rheumatism, brought together "probably the biggest and most diverse guidelines panel" ever assembled for a rheumatologic condition – with 51 members, including patients, according to Dr. Bhaskar Dasgupta, primary author of the guidelines and leader of the guidelines study group.

Within the guidelines is a flowchart for the treatment of polymyalgia rheumatica that outlines overarching principles for care involving clinical, laboratory, and imaging assessments, as well as patient views, said Dr. Dasgupta, head of the department of rheumatology at Southend University Hospital, Essex, England.

jevans@frontlinemedcom.com

PARIS – New guidelines aim to narrow the wide variation that has been observed across specialties and countries in the treatment of patients with polymyalgia rheumatica.

The guidelines, the first ever developed in a joint collaboration between the American College of Rheumatology and the European League Against Rheumatism, brought together "probably the biggest and most diverse guidelines panel" ever assembled for a rheumatologic condition – with 51 members, including patients, according to Dr. Bhaskar Dasgupta, primary author of the guidelines and leader of the guidelines study group.

Within the guidelines is a flowchart for the treatment of polymyalgia rheumatica that outlines overarching principles for care involving clinical, laboratory, and imaging assessments, as well as patient views, said Dr. Dasgupta, head of the department of rheumatology at Southend University Hospital, Essex, England.

jevans@frontlinemedcom.com

In November 2013, the American College of Cardiology and the American Heart Association published new U.S. cholesterol management guidelines, including a risk estimator.

The guidelines were released during the American Heart Association’s scientific sessions, and they stirred up some controversy. At the time, one of the attendees, Dr. Eugenia Gianos, the director of Preventive Cardiology fellowship at NYU Langone Medical Center, New York, was hesitant to use the new risk estimator.

However, in the past few months, Dr. Gianos said she has had the opportunity to apply these guidelines clinically, and has reviewed the recently released National Lipid Association’s draft "Recommendations for Patient-Centered Management of Dyslipidemia."

In a video interview, she shares what changed her view and what she has changed in her practice that could help other clinicians.

nmiller@frontlinemedcom.com

On Twitter @naseemmiller

In November 2013, the American College of Cardiology and the American Heart Association published new U.S. cholesterol management guidelines, including a risk estimator.

The guidelines were released during the American Heart Association’s scientific sessions, and they stirred up some controversy. At the time, one of the attendees, Dr. Eugenia Gianos, the director of Preventive Cardiology fellowship at NYU Langone Medical Center, New York, was hesitant to use the new risk estimator.

However, in the past few months, Dr. Gianos said she has had the opportunity to apply these guidelines clinically, and has reviewed the recently released National Lipid Association’s draft "Recommendations for Patient-Centered Management of Dyslipidemia."

In a video interview, she shares what changed her view and what she has changed in her practice that could help other clinicians.

nmiller@frontlinemedcom.com

On Twitter @naseemmiller

In November 2013, the American College of Cardiology and the American Heart Association published new U.S. cholesterol management guidelines, including a risk estimator.

The guidelines were released during the American Heart Association’s scientific sessions, and they stirred up some controversy. At the time, one of the attendees, Dr. Eugenia Gianos, the director of Preventive Cardiology fellowship at NYU Langone Medical Center, New York, was hesitant to use the new risk estimator.

However, in the past few months, Dr. Gianos said she has had the opportunity to apply these guidelines clinically, and has reviewed the recently released National Lipid Association’s draft "Recommendations for Patient-Centered Management of Dyslipidemia."

In a video interview, she shares what changed her view and what she has changed in her practice that could help other clinicians.

nmiller@frontlinemedcom.com

On Twitter @naseemmiller

CHICAGO – For the first time, researchers have shown that immunotherapy using adoptive T-cell therapy can induce complete remission in metastatic cervical cancer.

The study involved just nine patients given a single infusion of human papillomavirus (HPV)-targeted T cell therapy, but is sparking enormous excitement.

To learn more, watch our interview at the annual meeting of the American Society of Clinical Oncology with lead study author Dr. Christian Hinrichs of the National Cancer Institute.

The study was supported by the National Cancer Institute, National Institutes of Health. The authors reported no financial disclosures.

pwendling@frontlinemedcom.com

CHICAGO – For the first time, researchers have shown that immunotherapy using adoptive T-cell therapy can induce complete remission in metastatic cervical cancer.

The study involved just nine patients given a single infusion of human papillomavirus (HPV)-targeted T cell therapy, but is sparking enormous excitement.

To learn more, watch our interview at the annual meeting of the American Society of Clinical Oncology with lead study author Dr. Christian Hinrichs of the National Cancer Institute.

The study was supported by the National Cancer Institute, National Institutes of Health. The authors reported no financial disclosures.

pwendling@frontlinemedcom.com

CHICAGO – For the first time, researchers have shown that immunotherapy using adoptive T-cell therapy can induce complete remission in metastatic cervical cancer.

The study involved just nine patients given a single infusion of human papillomavirus (HPV)-targeted T cell therapy, but is sparking enormous excitement.

To learn more, watch our interview at the annual meeting of the American Society of Clinical Oncology with lead study author Dr. Christian Hinrichs of the National Cancer Institute.

The study was supported by the National Cancer Institute, National Institutes of Health. The authors reported no financial disclosures.

pwendling@frontlinemedcom.com

DALLAS – Constraint-induced movement therapy – a technique fairly well known for stroke – helps patients with hemiparetic multiple sclerosis, too.

Instead of favoring their good arm, patients are taught to use their affected arm. Once they learn how, the results seem to be self-perpetuating. That might be why Dr. Victor W. Mark and his colleagues at the University of Alabama at Birmingham found that the benefits of even a 10-day course of therapy persist for several years. They also found that constraint-induced movement therapy appears to help restore brain volume lost to MS.

Dr. Mark explained the technique and his findings at a meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis.

DALLAS – Constraint-induced movement therapy – a technique fairly well known for stroke – helps patients with hemiparetic multiple sclerosis, too.

Instead of favoring their good arm, patients are taught to use their affected arm. Once they learn how, the results seem to be self-perpetuating. That might be why Dr. Victor W. Mark and his colleagues at the University of Alabama at Birmingham found that the benefits of even a 10-day course of therapy persist for several years. They also found that constraint-induced movement therapy appears to help restore brain volume lost to MS.

Dr. Mark explained the technique and his findings at a meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis.

DALLAS – Constraint-induced movement therapy – a technique fairly well known for stroke – helps patients with hemiparetic multiple sclerosis, too.

Instead of favoring their good arm, patients are taught to use their affected arm. Once they learn how, the results seem to be self-perpetuating. That might be why Dr. Victor W. Mark and his colleagues at the University of Alabama at Birmingham found that the benefits of even a 10-day course of therapy persist for several years. They also found that constraint-induced movement therapy appears to help restore brain volume lost to MS.

Dr. Mark explained the technique and his findings at a meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis.